Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 12/20 | 0.54 |
| ▸ | CD38 | P28907 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 5/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2889848 | 0.99 | GCK (0.53) | GCKCD38EGFRFBP1ERBB2 | |
| SCHEMBL16131093 | 0.88 | GCK (0.55) | GCKCD38EGFRFBP1 | |
| SCHEMBL11948382 | 0.88 | GCK (0.43) | GCKEGFRFBP1 | |
| Hydrochloric Acid SCHEMBL2884071 | 0.87 | GCK (0.42) | GCKEGFRFBP1 | |
| SCHEMBL2892000 | 0.86 | GCK (0.49) | GCKEGFRFBP1 | |
| SCHEMBL11948383 | 0.84 | GCK (0.48) | GCKEGFR | |
| SCHEMBL2888232 | 0.84 | GCK (0.64) | GCKEGFR | |
| Hydrochloric Acid SCHEMBL2889791 | 0.83 | GCK (0.47) | GCKEGFR | |
| SCHEMBL11948388 | 0.83 | GCK (0.45) | GCKEGFRFBP1 | |
| Hydrochloric Acid SCHEMBL2889587 | 0.82 | GCK (0.44) | GCKEGFRFBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2221301-B1 | HETEROARYLOXY QUINAZOLINE DERIVATIVE | MSD KK (JP) | 2014-06-04 | — | — | EP | claimed |
| US-20100249146-A1 | HETEROARYLOXY QUINAZOLINE DERIVATIVE | MSD K.K. (JP) | 2010-09-30 | — | — | US | claimed |
| US-8846700-B2 | Heteroaryl quinazoline derivatives | MSD K.K. (JP) | 2014-09-30 | — | — | US | disclosed |
| EP-2221301-B1 | HETEROARYLOXY QUINAZOLINE DERIVATIVE | MSD KK (JP) | 2014-06-04 | — | — | EP | disclosed |
| US-20140011801-A1 | HETEROARYL QUINAZOLINE DERIVATIVES | MSD K.K. (JP) | 2014-01-09 | — | — | US | disclosed |
| US-8232284-B2 | Heteroaryloxy quinazoline derivative | MSD K. K. (JP) | 2012-07-31 | — | — | US | disclosed |
| US-8232284-B2 | Heteroaryloxy quinazoline derivative | MSD K. K. (JP) | 2012-07-31 | — | — | US | disclosed |
| US-20100249146-A1 | HETEROARYLOXY QUINAZOLINE DERIVATIVE | MSD K.K. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100249146-A1 | HETEROARYLOXY QUINAZOLINE DERIVATIVE | MSD K.K. (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249146-A1 | HETEROARYLOXY QUINAZOLINE DERIVATIVE | GCKR, GCK, KHK | GCK 2/4885CD38 2399/4885EGFR 4431/4885 |
| US-20140011801-A1 | HETEROARYL QUINAZOLINE DERIVATIVES | GCK, GCKR, KHK | GCK 1/4885CD38 2540/4885EGFR 4441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.